Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema.

Trial Profile

Chilean Interventional Open Label Pilot Study, to Assess the Efficacy and Safety of Lucentis (Ranibizumab Intravitreal Injections) in Patients With Visual Impairment Due to Diabetic Macular Edema.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 May 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Sponsors Novartis Pharmaceuticals
  • Most Recent Events

    • 02 May 2017 Status changed from active, no longer recruiting to completed.
    • 30 Jun 2016 Planned End Date changed from 1 Apr 2015 to 1 Jan 2017.
    • 30 Jun 2016 Planned primary completion date changed from 1 Apr 2015 to 1 Jan 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top